Hims & Hers Shares Double on Report of Wegovy Tie-Up

Dow Jones

Mar 09

By Joshua Kirby

Shares in telehealth company Hims & Hers skyrocketed in premarket trading following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform, a move that would end a legal spat between the two companies.

Hims & Hers, which markets consumer drugs ranging from treatments for weight loss and erectile dysfunction in men, to treatments for menopausal symptoms in women, is set to offer Novo Nordisk's blockbuster Wegovy on its platform, Bloomberg reported, citing an unnamed source.

Shares in Hims & Hers more than doubled in premarket trading to $23.92, according to Nasdaq data. Nordisk shares gained less dramatically in European morning trading, rising 1.4% to 251.45 Danish krone.

A tie-up would bring an end to a dispute between the company and Denmark-based Novo Nordisk, which last month filed a lawsuit against Hims & Hers that accused the company of violating patents covering Wegovy and fellow weight-loss treatment Ozempic. The company hit back at the lawsuit, which it described as an attack on a more affordable option.

Hims & Hers shares fell sharply following news of the lawsuit was revealed as investors feared a hit to sales.

Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby

(END) Dow Jones Newswires

March 09, 2026 05:58 ET (09:58 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2618642897"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618642897\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618642897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-09 17:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618642897","market":"fut","top_or_hot":-1,"title":"Hims & Hers Shares Double on Report of Wegovy Tie-Up","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Joshua Kirby \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares in telehealth company Hims &amp; Hers skyrocketed in premarket trading following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform, a move that would end a legal spat between the two companies. \n</p>\n<p>\n  Hims &amp; Hers, which markets consumer drugs ranging from treatments for weight loss and erectile dysfunction in men, to treatments for  menopausal symptoms in women, is set to offer <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s blockbuster Wegovy on its platform, Bloomberg reported, citing an unnamed source. \n</p>\n<p>\n  Shares in Hims &amp; Hers more than doubled in premarket trading to $23.92, according to Nasdaq data. Nordisk shares gained less dramatically in European morning trading, rising 1.4% to 251.45 Danish krone. \n</p>\n<p>\n  A tie-up would bring an end to a dispute between the company and Denmark-based Novo Nordisk, which last month filed a lawsuit against Hims &amp; Hers that accused the company of violating patents covering Wegovy and fellow weight-loss treatment Ozempic. The company hit back at the lawsuit, which it described as an attack on a more affordable option. \n</p>\n<p>\n  Hims &amp; Hers shares fell sharply following news of the lawsuit was revealed as investors feared a hit to sales. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 05:58 ET (09:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hims & Hers Shares Double on Report of Wegovy Tie-Up</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHims & Hers Shares Double on Report of Wegovy Tie-Up\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-09 17:58</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Joshua Kirby \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares in telehealth company Hims &amp; Hers skyrocketed in premarket trading following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform, a move that would end a legal spat between the two companies. \n</p>\n<p>\n  Hims &amp; Hers, which markets consumer drugs ranging from treatments for weight loss and erectile dysfunction in men, to treatments for  menopausal symptoms in women, is set to offer <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>'s blockbuster Wegovy on its platform, Bloomberg reported, citing an unnamed source. \n</p>\n<p>\n  Shares in Hims &amp; Hers more than doubled in premarket trading to $23.92, according to Nasdaq data. Nordisk shares gained less dramatically in European morning trading, rising 1.4% to 251.45 Danish krone. \n</p>\n<p>\n  A tie-up would bring an end to a dispute between the company and Denmark-based Novo Nordisk, which last month filed a lawsuit against Hims &amp; Hers that accused the company of violating patents covering Wegovy and fellow weight-loss treatment Ozempic. The company hit back at the lawsuit, which it described as an attack on a more affordable option. \n</p>\n<p>\n  Hims &amp; Hers shares fell sharply following news of the lawsuit was revealed as investors feared a hit to sales. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 09, 2026 05:58 ET (09:58 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2618642897","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618642897","pubTimestamp":1773050280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares in telehealth company Hims & Hers skyrocketed in premarket trading following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform, a move that would end a legal spat between the two companies.Hims & Hers, which markets consumer drugs ranging from treatments for weight loss and erectile dysfunction in men, to treatments for  menopausal symptoms in women, is set to offer Novo Nordisk's blockbuster Wegovy on its platform, Bloomberg reported, citing an unnamed source.Shares in Hims & Hers more than doubled in premarket trading to $23.92, according to Nasdaq data. Nordisk shares gained less dramatically in European morning trading, rising 1.4% to 251.45 Danish krone.A tie-up would bring an end to a dispute between the company and Denmark-based Novo Nordisk, which last month filed a lawsuit against Hims & Hers that accused the company of violating patents covering Wegovy and fellow weight-loss treatment Ozempic. The company hit back at the lawsuit","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","HIYY":"YieldMax HIMS Option Income Strategy ETF","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","HIMY":"Defiance Leveraged Long + Income HIMS ETF","NVOX":"2倍做多NVO ETF-Defiance","HMYY":"GraniteShares YieldBoost HIMS ETF","BK4585":"ETF&股票定投概念","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","HIMS":"Hims & Hers Health Inc.","HIMZ":"DEFIANCE DAILY TARGET 2X LONG HIMS ETF","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4007":"制药","NVOH":"Novo Nordisk A/S B Shares ADRhedged","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4196":"保健护理服务"},"translate_title":"Wegovy合作报道后Hims&Hers股价翻倍","themeId":"2125f643a531f294312a5aa84a9983ad","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1.97,"HIMZ":0.6,"HMYY":0.6,"HIMY":0.6,"NVOH":0.6,"HIYY":0.6,"NVOX":0.6},"content_text":"By Joshua Kirby \n\n\n \n\n\n  Shares in telehealth company Hims & Hers skyrocketed in premarket trading following a media report that the maker of Wegovy plans to sell the weight-loss drug on the platform, a move that would end a legal spat between the two companies. \n\n\n  Hims & Hers, which markets consumer drugs ranging from treatments for weight loss and erectile dysfunction in men, to treatments for  menopausal symptoms in women, is set to offer Novo Nordisk's blockbuster Wegovy on its platform, Bloomberg reported, citing an unnamed source. \n\n\n  Shares in Hims & Hers more than doubled in premarket trading to $23.92, according to Nasdaq data. Nordisk shares gained less dramatically in European morning trading, rising 1.4% to 251.45 Danish krone. \n\n\n  A tie-up would bring an end to a dispute between the company and Denmark-based Novo Nordisk, which last month filed a lawsuit against Hims & Hers that accused the company of violating patents covering Wegovy and fellow weight-loss treatment Ozempic. The company hit back at the lawsuit, which it described as an attack on a more affordable option. \n\n\n  Hims & Hers shares fell sharply following news of the lawsuit was revealed as investors feared a hit to sales. \n\n\n \n\n\n  Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 05:58 ET (09:58 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}